- Home
- / Ergomed
Ergomed
Revenue
£145.3 M
FY, 2022
Ergomed Summary
Company Summary
- Overview
- Ergomed Group is a company that provides drug development services to the pharmaceutical industry. It offers clinical research and trial management services, as well as pharmacovigilance solutions. The company specializes in oncology and rare disease trials. Ergomed Group operates in the pharmaceutical and biotechnology industries.
- Type
- Private
- Status
- Active
- Founded
- 1997
- HQ
- Guildford, GB | view all locations
- Website
- https://ergomedgroup.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Sy Pretorius, Chief Executive Officer
Jonathan Curtain, Chief Financial Officer
Dave Selkirk, President, Clinical Research
Operating MetricsView all
Order Book
£295M
23.1%
FY, 2022
Countries
140
FY, 2021
Patients
190K
FY, 2022
LocationsView all
1 location detected
Guildford, England HQ
United Kingdom
Occam Court, Occam Rd
Ergomed Financials
Summary Financials
- Revenue (FY, 2022)
- £145.3M
- Gross profit (FY, 2022)
- £60.3M
- Net income (FY, 2022)
- £15.0M
- Cash (FY, 2022)
- £19.1M
- EBIT (FY, 2022)
- £19.3M